Clinicopathological characteristics and survival of spinal cord astrocytomas

Yao-Wu Zhang1,2 | Rui-Chao Chai2,3,4 | Ren Cao1,2 | Wen-Ju Jiang1,2 | Wei-Hao Liu1,2 | Yu-Lun Xu1,2 | Jun Yang1,2 | Yong-Zhi Wang1,2,3,4 | Wen-Qing Jia1,2

1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2China National Clinical Research Center for Neurological Diseases, Beijing, China
3Department of Molecular Neuropathology, Beijing neurosurgical institute, Capital Medical University, Beijing, China
4Chinese Glioma Genome Atlas Network (CGGA), Beijing, China

Correspondence
Wen-Qing Jia and Yong-Zhi Wang,
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
Emails: coffeeend@163.com (W.-Q. J.) and yongzhiwang_bni@163.com (Y.-Z. W.)

Funding information
This study was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16040303), the National Natural Science Foundation of China (81891004, 81903078, 81773208), the Capital Characteristic Clinical Application Research and Achievement Promotion Project of China (Z17110001017068), and the National Key Research and Development Program of China (2018YFC0115604).

Abstract
Background: Due to their rarity, the clinicopathological characteristics and prognostic factors of spinal cord gliomas are still unclear. Here, we aimed to clarify these issues in a cohort of 108 spinal cord astrocytomas.

Methods: We characterized the clinicopathological characteristics, including 2016 World Health Organization (WHO) grade, age, sex, location, segment length, resection, pre- and postsurgery, Modified McCormick Scale (MMS), radio- and chemotherapy, and Ki-67 and H3 K27M mutations, in 108 spinal cord astrocytomas through heatmaps. The Cox regression analysis and Kaplan-Meier curves were used to study the prognostic value of these clinicopathological features.

Results: There are a total 38 H3 K27M-mutant tumors, including 31 cases with histological grade II/III tumors. The age of low-grade astrocytoma patients (WHO grade I/II, n = 54) was significantly younger (27.0 vs 35.5 years, \( P = .001 \)) than those with high-grade tumors (WHO grade III/IV, n = 54). All patients underwent surgical resection with neurophysiological monitoring, and the surgery did not result in significant changes in MMS. The presurgery MMS was associated with overall survival in the high-grade subgroup (\( P = .008 \)) but not in the low-grade subgroup (\( P = .475 \)). Both the low-grade and high-grade astrocytomas had no obvious benefit from neither adjuvant chemotherapy nor radiotherapy (all \( P > .05 \)).

Conclusions: We characterized the clinicopathological characteristics and their prognostic values in 108 spinal cord astrocytomas, which could help with evidence-based management of spinal cord astrocytomas.

Keywords
astrocytoma, clinicopathological feature, H3 K27M, spinal cord tumor, survival
1 | INTRODUCTION

Spinal cord gliomas (including those of the cauda equina) are relatively uncommon neoplasms, accounting for approximately 4.2% of all central nervous system (CNS) gliomas, of which 20%-40% are astrocytomas and the rest are ependymomas. Although treatment guidelines for brain gliomas, prognostic molecular markers, and prognostic markers associated with chemo- and radiotherapy have been established, spinal cord gliomas are considerably different from brain gliomas in terms of biological behaviors and molecular profiles. Special treatment guidelines are yet to be established for spinal cord gliomas because of their relatively rare incidence, and the characteristics and prognostic factors of spinal cord astrocytomas remain largely unknown.

Previous studies have investigated the prognostic factors of spinal cord astrocytomas. However, most of these studies are small samples or multicenter, and the findings are inconsistent, such as the effect of surgical extent on the prognosis of low-grade or high-grade spinal cord astrocytomas. The schemes and effects of adjuvant radiotherapy or chemotherapy vary from institution to institution.

“Diffused midline glioma, H3 K27M-mutant” has been defined as a new entity in the 2016 World Health Organization (WHO) classification of Central Nervous System (CNS) tumors, corresponding to WHO grade IV. It mainly occurs in the midline structure of the thalamus, brainstem, and spinal cord. Some studies have reported “diffuse midline glioma, H3 K27M-mutant” in the midline structure including spinal cord. However, based on the 2016 WHO classification, the clinicopathological characteristics of spinal cord astrocytomas are rarely reported. It remains challenging to manage spinal cord astrocytomas with evidence-based practices. Therefore, it is urgent to summarize the characteristics and prognostic factors of spinal cord astrocytomas from a relatively large number of patients based on the 2016 WHO classification.

This study aimed to determine the clinical characteristics and prognostic factors of spinal cord astrocytomas based on the 2016 WHO classification through a retrospective analysis of 108 patients. Our findings will provide information on the overall median survival (OS) of patients with spinal cord astrocytomas of different WHO grades. We also compared the clinicopathological characteristics and prognostic impacts of interventions between low-grade (WHO grade I/II) and high-grade (WHO grade III/IV) gliomas.

2 | MATERIALS AND METHODS

2.1 | Patient population

We reviewed 108 patients who underwent open surgical resection and who were pathologically confirmed to have spinal cord astrocytomas at our hospital from 2011 to 2018. Among all patients, three were excluded from the final survival analysis because of loss to follow-up (n = 2) or death during the perioperative period (n = 1). The patient demographics, including age, sex, tumor location, histology, radiotherapy, and chemotherapy, are shown in Table 1.

2.2 | Neuropathologic evaluation

Routine neuropathologic evaluation of the formalin-fixed and paraffin-embedded tumor samples included hematoxylin and eosin staining and immunohistochemical analysis performed using antibodies against mutant H3 K27M (ABE419; Millipore; 1:800) and Ki-67 (MIB-1; Labvision; 1:50). K27M-mutant gliomas were classified as grade IV according to the 2016 WHO Classification of Tumors of the Central Nervous System.

2.3 | Treatment modality

The posterior midline approach with the lateral oblique side of the lesion in the upper position was adopted for all cases, and laminectomy was customized for solid tumors. We routinely used sensory and motor evoked potentials in microsurgical resection. While monitoring the changes in sensory and motor evoked potentials, we attempted to perform maximal resection of the tumor according to the extent allowed by the spinal cord function. If the presence of sensory or motor evoked potentials sustained decrease >50% of the baseline or the surgical plane could not be identified, dissection was stopped, and gentle manipulation was considered during the whole procedure. If the spinal cord is severely swollen before surgery, laminectomy was performed for decompression. Surgical interventions and subsequent medical management were performed by the same group of surgeons, following identical procedures. Neurological functional status was retrospectively evaluated using the Modified McCormick Scale (MMS).

The extent of resection (EOR) was estimated using post-surgery magnetic resonance images (MRI). Based on the MRI results, EOR was defined as gross total resection (≥90%), subtotal resection (≥50% and <90%), and open biopsy (<50%). The EOR was independently determined by two experienced radiologists, who were blinded to the clinical data of the patients. In case of a discrepancy, the two observers simultaneously reviewed the images to achieve a consensus.

Owing to the lack of standard chemo- and radiotherapy regimens for spinal cord gliomas, the chemoradiotherapy regimen for spinal cord gliomas is based on the treatment protocol for brain gliomas, according to the National Comprehensive Cancer Network (NCCN) guidelines. The postsurgery conventional adjuvant radiotherapy total dose was 40-50 Gy, which was administered at a dose.
of 1.8-2.0 Gy per fraction per day for 5 days per treatment week over 5 consecutive weeks (23-25 days). The chemotherapy regimen adopted temozolomide, administered at a daily dose of 75 mg/m$^2$ during radiotherapy or at a daily dose of 150/200 mg/m$^2$ for 5 consecutive days per treatment week over 4 weeks per cycle.

| Variable | All patients (N = 108) | Low-grade (N = 54) | High-grade (N = 54) | P-value$^a$ |
|----------|------------------------|-------------------|---------------------|-------------|
| Age (y)  | Median (range)         |                   |                     | .001        |
|          | 30.0 (4-63)            | 27.0 (4-54)       | 35.5 (8-63)         |             |
| Sex      | Female                 |                   |                     | .074        |
|          | 41 (38.0%)             | 16 (29.6%)        | 25 (46.3%)          |             |
|          | Male                   | 67 (62.0%)        | 38 (70.4%)          |             |
|          | 29 (53.7%)             |                   |                     |             |
| Location | C                      |                   |                     | .896        |
|          | 40 (37.0%)             | 21 (38.9%)        | 19 (35.2%)          |             |
|          | C-T                    | 16 (14.8%)        | 8 (14.8%)           |             |
|          | 8 (14.8%)              |                   |                     |             |
|          | T                      | 44 (40.8%)        | 22 (40.7%)          |             |
|          | T-L                    | 8 (7.4%)          | 3 (5.6%)            |             |
|          | 5 (9.3%)               |                   |                     |             |
| Segment length | Average | 3.91 | 3.78 | 4.04 | .434 |
| Resection | GTR                    | 58 (53.7%)        | 35 (64.8%)          | .054        |
|          | STR                    | 18 (16.7%)        | 8 (14.8%)           |             |
|          | OB                     | 32 (29.6%)        | 11 (20.4%)          |             |
|          | 21 (38.9%)             |                   |                     |             |
| Presurgery MMS | 1 | 4 (3.7%) | 3 (5.7%) | 1 (1.9%) | <.001 |
|          | 2                      | 50 (46.7%)        | 37 (69.8%)          |             |
|          | 3                      | 36 (33.6%)        | 10 (18.9%)          |             |
|          | 4                      | 17 (15.9%)        | 3 (5.7%)            |             |
|          | NA                     | 1                 | 1                   | 0           |
| Postsurgery MMS | 1 | 5 (4.7%) | 4 (7.5%) | 1 (1.9%) | <.001 |
|          | 2                      | 39 (36.4%)        | 31 (58.5%)          |             |
|          | 3                      | 44 (41.1%)        | 16 (30.2%)          |             |
|          | 4                      | 19 (17.8%)        | 2 (3.8%)            |             |
|          | NA                     | 1                 | 1                   | 0           |
| Radiotherapy | Yes                    | 62 (67.4%)        | 32 (66.7%)          | .877        |
|          | No                     | 30 (32.6%)        | 16 (33.3%)          |             |
|          | NA                     | 16                | 6                   | 10          |
| Chemotherapy | Yes                    | 27 (29.3%)        | 8 (16.7%)           | .005        |
|          | No                     | 65 (70.7%)        | 40 (83.3%)          |             |
|          | NA                     | 16                | 6                   | 10          |
| Ki-67    | <10%                   | 53 (51.0%)        | 42 (82.4%)          | <.001       |
|          | ≥10%                   | 51 (49.0%)        | 9 (19.6%)           |             |
|          | NA                     | 4                 | 3                   | 1           |
| H3 K27M  | Negative               | 62 (62.0%)        | —                   |             |
|          | Positive               | 38 (38.0%)        | —                   |             |
|          | NA                     | 8$^b$             | 7                   | 1           |

Note: Significance of bold values $P < .05$. Abbreviations: C, cervical; C-T, cervicothoracic; GTR, gross total resection; MMS, Modified McCormick Scale; NA, not available; OB, open biopsy; STR, subtotal resection; T, thoracic; T-L, thoracolumbar.

$^a$P-values for the t test or Chi-squared test or Mann-Whitney U test used to compare low-grade and high-grade tumors.

$^b$Patients before 2016 without data on H3 K27M mutation and without adequate tissue sample available for added immunohistochemistry, including 2, 5, and 1 patient with grade I, II, and III tumors, respectively.
2.4 Statistical analysis

The characteristics of patients and lesions are presented by descriptive statistics. Differences in age were analyzed using the t-test, and categorical variables were analyzed using the Chi-squared test or Mann-Whitney U test. OS was defined as the period from the date of surgery to the date of last follow-up or death. Prognostic factors and survival were analyzed, and the results were compared using the Kaplan-Meier and log-rank tests and univariate and multivariate Cox regression. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. Survival rates were calculated at 1 year, 3 years, 5 years, and median survival times (standard error, 95% CI). All P-values < .05 were considered statistically significant, and statistical analyses were conducted using IBM SPSS Statistics software (Release 23.0.0) and GraphPad Prism 7 (GraphPad Software).

3 RESULTS

3.1 Baseline demographics

The characteristics of the patients are shown in Figure 1A and Table 1. The male-to-female ratio was 1.6:1. The median age at the time of diagnosis was 30.0 years (range, 4-63 years). Patients with low-grade astrocytomas were younger than those with high-grade tumors (median age, 27.0 vs 35.5 years; P = .001). The thoracic vertebrae (40.8%) were the most common tumor locations, followed by the cervical (37.0%), cervicothoracic (14.8%), and thoracolumbar (7.4%) vertebrae. There was no significant correlation between pathological grading and tumor location (P = .896). The average tumor span was 3.91 segments, and the tumor span between low- and high-grade astrocytomas showed no significant difference (P = .434).

All patients underwent open surgical resection with neuropsychological monitoring. Fifty-eight patients (53.7%) underwent gross total resection, 18 (16.7%) underwent subtotal resection, and the rest (29.6%) had open biopsy. A remarkable difference in EOR was found between low-grade and high-grade astrocytomas, and the open biopsy ratio was increased in high-grade astrocytomas (38.9% vs 20.4%, P = .054, Table 1). Among patients with low-grade astrocytomas, 75.5% had a presurgery MMS of grade 1 or 2, while 74.0% of those with high-grade astrocytomas had a presurgery MMS of grade 3 or 4. The presurgery MMS of patients with high-grade tumor was significantly higher than those of patients with low-grade tumor (P < .001). Presurgery and postsurgery changes in MMS are shown in Figure 1B. The surgery did not significantly change the MMS in patients with low-grade tumor (P = .613), it
slightly increased the MMS in patients with high-grade tumor, but the increase was not insignificant \( (P = .058, \text{Figure 1C}) \). Information on post-surgery adjuvant chemo- and radiotherapy was available in 92 patients (85.2%). Among them, 66.7% of those with low-grade tumors and 68.2% of those with high-grade tumors received adjuvant radiotherapy \( (P = .877) \). A higher ratio of patients with high-grade tumors (43.2% vs 16.7%, \( P = .005 \)) received chemotherapy.

In this study, the positive rate of H3 K27M mutation was 38%, and 31 histological grade II/III gliomas with H3 K27M mutation were diagnosed as WHO grade IV gliomas. Grade I, II, III, and IV gliomas were diagnosed in 15 (13.9%), 39 (36.1%), 10 (9.3%), and 44 (40.7%) patients, respectively. Ki-67 showed a high expression rate (≥10%) in almost 80% of cases of high-grade astrocytomas (WHO grade III/IV), which was remarkably higher \( (P < .001) \) than in cases of low-grade tumors (WHO grade I/II).

### 3.2 OS in low-grade and high-grade astrocytomas

Follow-up data were available in 106 patients (98.0%). The median follow-up time was 50.2 months after surgery, and 45 patients died during the period. The Kaplan-Meier estimates of OS according to WHO grades are shown in Figure 2. The median OS time of patients with grade IV tumors was 20.2 months, while that of patients with grade I, II, or III tumors was not reached. All patients with grade I tumors survived until the last follow-up. Meanwhile, the 1-, 3-, and 5-year OS rates were 92%, 86%, and 77% for grade II tumors, 76%, 76%, and 61% for grade III tumors, and only 68%, 29%, and 7% for grade IV tumors, respectively.

### 3.3 Prognostic factors of low-grade and high-grade astrocytomas

Univariate Cox regression analyses of clinicopathological factors are shown in Table 2. For all patient groups, older age

| Variable                       | All patients                     | Low-grade                                | High-grade                               |
|--------------------------------|----------------------------------|------------------------------------------|------------------------------------------|
|                                | Hazard ratio (95% CI) P           | Hazard ratio (95% CI) P                  | Hazard ratio (95% CI) P                  |
| Age (y)                        | 1.03 (1.01-1.05) .007             | 1.03 (0.97-1.09) .323                    | 1.00 (0.98-1.03) .763                    |
| Sex (male)                     | 0.60 (0.33-1.08) .089             | 1.04 (0.20-5.39) .959                    | 0.70 (0.37-1.33) .275                    |
| WHO grade (I-IV)               | 3.33 (2.24-4.96) <.001            | 33.04 (0.03-44265.88) .341               | 4.06 (1.23-13.42) .021                   |
| Location (C, C-T, T, T-L)      | 0.92 (0.70-1.22) .574             | 1.00 (0.49-2.04) .989                    | 0.86 (0.64-1.16) .325                    |
| Segment length                 | 1.13 (0.96-1.34) .152             | 0.87 (0.53-1.43) .586                    | 1.19 (0.99-1.44) .066                    |
| Presurgery MMS (1-4)           | 2.77 (1.87-4.10) <.001            | 1.70 (0.61-4.79) .312                    | 1.99 (1.20-3.31) .008                    |
| Resection (GTR, STR, PR)       | 1.78 (1.28-2.47) .001             | 2.89 (1.24-6.74) .014                    | 1.26 (0.86-1.83) .231                    |
| Radiotherapy                   | 0.82 (0.40-1.68) .586             | 0.78 (0.14-4.32) .777                    | 0.69 (0.31-1.53) .357                    |
| Chemotherapy                   | 1.86 (0.95-3.63) .070             | 0.89 (0.10-7.59) .911                    | 1.05 (0.51-2.19) .890                    |
| Ki-67 expression (≥10%)        | 6.33 (3.09-12.93) <.001            | 1.90 (0.37-9.79) .445                    | 3.47 (1.33-9.02) .011                    |

**Note:** Significance of bold values \( P < .05 \).

**Abbreviations:** C, cervical; CI, confidential interval; C-T, cervicothoracic; GTR, gross total resection; MMS, Modified McCormick Scale; PR, partial resection or open biopsy; STR, subtotal resection; T, thoracic; T-L, thoracolumbar.
(HR, 1.03; 95% CI, 1.01-1.05; \(P = .007\)), higher WHO grade (HR, 3.33; 95% CI, 2.24-4.96; \(P < .001\)), lower EOR (HR, 1.78; 95% CI, 1.28-2.47; \(P = .001\)), higher presurgery MMS (HR, 2.77; 95% CI, 1.87-4.10; \(P < .001\)), and Ki-67 expression rate \(\geq 10\%\) (HR, 6.33; 95% CI, 3.09-12.93; \(P < .001\)) were significantly associated with worse survival. For low-grade gliomas, EOR was significantly correlated with OS (HR, 2.89; 95% CI, 1.24-6.74; \(P = .014\)). For high-grade gliomas, WHO grade (HR, 4.06; 95% CI, 1.23-13.42; \(P = .021\)), presurgery MMS (HR, 1.99; 95% CI, 1.20-3.31; \(P = .008\)), and Ki-67 expression (HR, 3.47; 95% CI, 1.33-9.02; \(P = .011\)) were significantly correlated with OS. The Kaplan-Meier curves also indicated that the EOR could significantly stratify the OS of all astrocytoma patients (\(P = .0017\), Figure 3A) or the low-grade astrocytoma subgroup (\(P = .0157\), Figure 3B), but not the OS of the high-grade astrocytoma subgroup (\(P = .4749\), Figure 3C). It was noteworthy that both adjuvant radiotherapy and chemotherapy did not have a significant effect on median survival time for both low-grade and high-grade tumors (Figure 3D-G).

We also performed a multivariate Cox regression analysis of factors with \(P\)-values < .05 in the univariate analysis for all astrocytoma patients or the high-grade astrocytoma subgroup, including age, WHO grade, presurgery MMS, resection, and Ki-67 expression (Table 3). Among all patients, WHO grade (HR, 2.08; 95% CI, 1.29-3.37; \(P = .003\)), presurgery MMS (HR, 1.69; 95% CI, 1.02-2.77; \(P = .040\)), and Ki-67 expression (HR, 2.43; 95% CI, 1.09-5.40; \(P = .029\)) were the independent prognostic factors for OS. In the high-grade tumor group, presurgery MMS (HR, 1.86; 95% CI, 1.06-3.27; \(P = .031\)) and Ki-67 expression (HR, 2.80; 95% CI, 1.00-7.83; \(P = .049\)) were the independent prognostic factors for survival.

### 3.4 | Illustrative cases

#### 3.4.1 | Case 1

A 48-year-old male presented with numbness and weakness of right lower limb. Presurgery neurological assessment...
showed grade IV muscle strength in the right lower limb. The grade of presurgery MMS was 2. Presurgery T2-weighted MRI revealed slightly swollen thoracic cord at the T2-T7 level, and enhanced T1-weighted MRI showed thoracic cord nodular-like enhancement at the T5-T6 level (Figure 4A,B). T2-weighted and enhanced T1-weighted images 1 week after surgery are shown in Figure 4C,D. He underwent gross total resection, and the histopathology identified a diffuse astrocytoma (WHO grade II, Figure 4E). The H3 K27M analysis was negative (Figure 4F), and the percentage of Ki-67-positive cells was 3%-5%. Postsurgery neurological assessment showed grade IV muscle strength in both lower limbs. He received adjuvant radiotherapy after surgery. At the last follow-up (56.8 months), he demonstrated grade III muscle strength of the lower limbs and grade IV muscle strength of the upper limbs. This observation was consistent with our finding that lower WHO grade, lower presurgery MMS, higher EOR, and Ki-67 expression rate <10% were significantly associated with better survival in low-grade gliomas.

### 3.4.2 Case 2

A 46-year-old female exhibited dizziness, nausea, vomiting, numbness of the limbs, and weakness of the lower limbs. Presurgery neurological assessment showed grade IV muscle strength in the limbs, increased muscular tension, and sensory decline. The grade of presurgery MMS was 4. Presurgery MRI revealed diffuse spinal cord swelling, T2-weighted MRI showed a high inhomogeneous signal in the spinal cord at the C4-T1 level, and enhanced T1-weighted MRI showed lesions with significant and relatively homogeneous enhancement (Figure 5A,B). Presurgery enhanced T1-weighted MRI of the brain showed lesions with enhancement (Figure 5C,D). Postsurgery neurological assessment showed grade III-IV muscle strength in limbs and decreased sensation. T2-weighted and enhanced T1-weighted images 1 week after surgery are shown in Figure 5E,F. The histopathology identified an anaplastic astrocytoma, scattered with massive tumor giant cells, with occasional focal necrosis (WHO III-IV, Figure 5G), the H3 K27M analysis was positive (Figure 5H), and the percentage of Ki-67-positive cells was 20%. Although she underwent gross total resection of the spinal cord lesions and received adjuvant radiotherapy after surgery, her survival was only 8.4 months. This observation was consistent with the conclusion of this study that higher WHO grade, higher presurgery MMS, and Ki-67 expression rate ≥10% were significantly associated with worse survival in high-grade gliomas.

Previous studies have reported intracranial spread of spinal cord astrocytoma.24-26 In case 2, the patient had symptoms such as dizziness, nausea, and vomiting before surgery, and the MRI of the brain showed abnormal enhancement of the ventricular wall, so the preoperative intracranial dissemination of the tumor was considered. Due to the development of the disease, the patient did not review the MRI of the brain and cervical spine, and eventually died of coma and dyspnea. The tumor site of the patient was located in the cervical enlargement (C4-T1), and the recurrence of the original site may lead to limb paralysis without conscious coma. Therefore, we speculate that tumor dissemination may be the most important cause of respiratory center failure and conscious coma.

### 4 DISCUSSION

Due to the rarity of spinal cord astrocytomas, their treatment remains controversial and there are no established special treatment guidelines.7 Here, we summarized the clinicopathological

| Variable               | All patients (N = 108) | High-grade (N = 54) |
|------------------------|------------------------|---------------------|
|                        | Hazard ratio (95% CI)  | P-value             | Hazard ratio (95% CI) | P-value |
| Age (y)                | 1.01 (0.98-1.03)       | .656                | NT                   | —       |
| WHO grade (I-IV)       | 2.08 (1.29-3.37)       | .003                | 2.42 (0.70-8.35)     | .163    |
| Presurgery MMS (1-4)   | 1.69 (1.02-2.77)       | .040                | 1.86 (1.06-3.27)     | .031    |
| Resection (GTR, STR, PR) | 1.25 (0.87-1.79)       | .227                | NT                   | —       |
| Ki-67 expression (≥10%)| 2.43 (1.09-5.40)       | .029                | 2.85 (1.07-7.55)     | .036    |

Note: Significance of bold values P < .05.
Abbreviations: CI, confidential interval; GTR, gross total resection; MMS, Modified McCormick Scale; NT, not tested; PR, partial resection or open biopsy; STR, subtotal resection.

### Table 3 Multivariate analysis of the clinicopathological features of all patients and the high-grade spinal cord astrocytoma subgroup
characteristics and prognostic factors of spinal cord astrocytomas based on the 2016 WHO classification in 108 patients. Compared with previous studies on diffuse intrinsic pontine gliomas (DIPGs), our study revealed an older age at diagnosis (median, 30 years; range, 4-63 years), a lower ratio of H3 K27M mutation (38%), and a longer OS (48.1 months) among patients with spinal cord astrocytomas. We also identified that age at diagnosis, WHO grade, presurgery MMS, EOR, and Ki-67 expression were significantly associated with OS in these patients. Furthermore, a higher EOR was significantly correlated with better survival in patients with low-grade astrocytomas but not in those with high-grade astrocytomas. In patients with high-grade astrocytomas, a higher WHO grade, higher presurgery MMS, and Ki-67 expression rate of ≥10% were negatively correlated with OS. These findings could provide a basis for evidence-based practices for managing spinal cord astrocytomas.

In this study, the median age at diagnosis was 30.0 years (range, 4-63 years). These findings are significantly different from those of previous studies on DIPGs in which the median age at diagnosis was 6-7 years. Although histological grade is not a prognostic factor of DIPGs, our study revealed that patients with low-grade astrocytomas were younger and had longer survival than those with high-grade astrocytomas. This finding is consistent with previous findings showing that histological grade is an important prognostic factor and that patients with high-grade (grade III/IV) tumors experienced a worse prognosis.

We also identified that the median OS of patients with grade IV tumors was 20.2 months, significantly longer than that reported (<1 year) for patients with DIPGs. Moreover, the H3 K27M mutation rate was 38%, much lower than the nearly 80% rate in DIPGs. All these findings indicate that spinal cord astrocytomas are different from DIPGs, and the characteristics of H3 K27M-mutant gliomas should be considered separately based on their location.

The impact of EOR on the prognosis of spinal cord astrocytomas is different between low-grade and high-grade astrocytomas. Ryu et al reported that EOR was not associated with prognosis in patients with high-grade astrocytomas (total, 26 cases). A study of 561 low-grade (WHO grade I/II) astrocytomas indicated that gross total resection could significantly improve survival (HR, 0.22; P < .001). Meanwhile, our study involved all glioma grades and also demonstrated that EOR had a positive effect on survival among patients with low-grade astrocytomas but not among patients with high-grade astrocytomas. This finding is inconsistent with previous findings on brain gliomas in which the EOR was not significantly associated with survival in patients with low-grade (WHO grade II) brain gliomas but showed a statistical significance for high-grade (WHO grade III/IV) brain gliomas. Therefore, the treatment for brain gliomas may not be suitable for spinal cord gliomas, and it is urgent to develop a series of standard treatment regimens for spinal cord gliomas.

Consistent with a previous study, the presurgery MMS in this study was significantly higher in high-grade astrocytomas than in low-grade tumors. All patients underwent surgical resection with neurophysiological monitoring and the surgery did not result in significant changes in MMS. The presurgery neurological functional status was associated with OS in all astrocytoma patients or those with high-grade astrocytomas, but not in the low-grade astrocytoma subgroup. Thus, surgery should achieve a greater EOR while preserving neurological function.

The chemoradiotherapy regimen for spinal cord gliomas is mainly based on the treatment protocol for brain gliomas. Radiotherapy has a significant positive effect on OS for all patients with brain gliomas, including low-grade gliomas, while chemotherapy has a significant survival benefit only in patients with glioblastomas. The efficacy of adjuvant radiotherapy or chemotherapy for spinal cord astrocytoma still remains controversial. In this study, we found that both adjuvant chemo- and radiotherapy did not have a significant effect on OS for both low-grade and high-grade astrocytomas.

**FIGURE 4** Case 1: Images of an H3 K27M mutation-negative tumor in a 48-year-old male whose cardinal symptoms were numbness and weakness in the right lower limb. The histopathology identified a diffuse astrocytoma (WHO grade II). (A, B) Presurgery T2-weighted and enhanced T1-weighted magnetic resonance images (MRI). (C, D) Postsurgery T2-weighted and enhanced T1-weighted MRI. (E) Diffuse astrocytoma (H&E, 200×). (F) H3 K27M mutation-negative tumor (H3 K27M, 200×). H&E, hematoxylin and eosin staining.
tumors (all $P > .05$). This result may be related to the low dose of radiotherapy tolerated by the spinal cord and the injury caused by the radiation. Generally, a lower dose (45-50 Gy) of radiation is administered, and the curative effect is poor.

Although this study involved a large cohort of patients with spinal cord astrocytomas, the sample size is still relatively small, and the power to assess potential predictive characteristics is limited. Aside from having a retrospective design, the study lacked sufficient molecular pathological information. Further prospective studies are needed to address these issues. This study provides data on the characteristics and prognostic factors of spinal cord astrocytomas in the Asian population and has the largest sample of patients with such tumors based on the 2016 WHO classification in a single institution. The findings could be useful for evidence-based management of spinal cord astrocytomas.

**CONFLICT OF INTEREST**
The authors declare that they have no competing interests.

**AUTHOR CONTRIBUTIONS**
Yao-Wu Zhang wrote the manuscript. Rui-Chao Chai and Yong-Zhi Wang carefully revised and proofread the manuscript. Yao-Wu Zhang, Rui-Chao Chai, and Yong-Zhi Wang designed the experiment, conducted the information collection, and data analysis. Ren Cao, Wen-Ju Jiang, and Wei-Hao Liu collected the clinical information and proofread the manuscript. Yu-Lun Xu, Jun Yang, and Wen-Qing Jia conducted the study design and proofread the manuscript. Wen-Qing Jia and Yong-Zhi Wang supervised the work.

**ETHICAL STATEMENTS**
This retrospective study was approved by the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical
University (Beijing, China), and informed consent had been obtained from each patient involved in our study.

DATA AVAILABILITY STATEMENT
The data sets used and/or analyzed in this study are available from the corresponding author upon reasonable request.

ORCID
Rui-Chao Chai https://orcid.org/0000-0003-3451-8871
Yong-Zhi Wang https://orcid.org/0000-0003-3276-6329
Wen-Qing Jia https://orcid.org/0000-0003-2893-9784

REFERENCES
1. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(1):iv1-iv86.
2. Hu H, Mu Q, Bao Z, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018;175(6):1665-1678.e18.
3. Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016;375:263-273.
4. Chai R-C, Li Y-M, Zhang K-N, et al. RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight. 2019;5(17):e130591.
5. Chai R-C, Liu Y-Q, Zhang K-N, et al. A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Mod Pathol. 2019;32:4-15.
6. Chai R-C, Zhang K-N, Chang Y-Z, et al. Systematically characterize the clinical and biological significances of 1p19q genes in 1p19q non-codelletion glioma. Carcinogenesis. 2019;40:1229-1239.
7. Chai R-C, Zhang Y-W, Liu Y-Q, et al. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun. 2020;8:40.
8. Abd-El-Barr MM, Huang KT, Moses ZB, Iorgulescu JB, Chi JH. Recent advances in intradural spinal tumors. Neuro Oncol. 2018;20:729-742.
9. Fakhreddine MH, Mahajan A, Penas-Prado M, et al. Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro Oncol. 2013;15:406-412.
10. Babu R, Karikari IO, Owens TR, Bagley CA. Spinal cord astrocytomas: a modern 20-year experience at a single institution. Spine (Phila Pa 1976). 2014;39:533-540.
11. Ryu SJ, Kim JY, Kim KH, et al. A retrospective observational study on the treatment outcomes of 26 patients with spinal cord astrocytoma including two cases of malignant transformation. Eur Spine J. 2016;25:4067-4079.
12. Seki T, Hida K, Yano S, Aoyama T, Koyanagi I, Houkin K. Surgical outcomes of high-grade spinal cord gliomas. Asian Spine J. 2015;9:935-941.
13. Adams H, Avendaño J, Raza SM, Gokaslan ZL, Jallo GI, Quiñones-Hinojosa A. Prognostic factors and survival in primary malignant astrocytomas of the spinal cord. Spine. 2012;37:E727-E735.
14. Liu J, Zheng M, Yang W, Lo SL, Huang J. Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study. J Neurooncol. 2018;139:609-616.
15. Díaz-Aguilar D, ReFaey K, Clifton W, et al. Prognostic factors and survival in low grade gliomas of the spinal cord: a population-based analysis from 2006 to 2012. J Clin Neurosci. 2019;61:14-21.
16. Zou Y, Sun J, Zhou Y, et al. Prognostic factors and treatment of spinal astrocytomas: a multi-institutional cohort analysis. Spine (Phila Pa 1976). 2018;43(10):E656-E673.
17. Yi S, Choi S, Shin DA, et al. Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of new 2016 World Health Organization classification of the central nervous system. Neurosurgery. 2019;84(5):1072-1081.
18. Kaley TJ, Mondesire-Crump I, Gavrilovic IT. Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol. 2012;109:385-389.
19. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-820.
20. Solomon DA, Wood MD, Tihan T, et al. Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26:569-580.
21. Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol. 2017;19:1127-1134.
22. Karremann M, Gielen GH, Hoffmann M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018;20:123-131.
23. Kim MS, Chung CK, Choe G, Kim IH, Kim HJ. Intramedullary spinal cord astrocytoma in adults: postoperative outcome. J Neurooncol. 2001;52:85-94.
24. Yan C, Kong X, Yin H, et al. Glioblastoma multiforme in conus medullaris with intracranial metastasis after postoperative adjuvant therapy. Medicine (Baltimore). 2017;96:e6500.
25. Schlereth T, Nguyen-Huu BK, Muller H, Sommer C, Muller-Forell W, Zipp F. Intracranial spreading of a spinal anaplastic astrocytoma. J Neurol. 2012;259:768-770.
26. Tendulkar RD, Pai Panandiker AS, Wu S, et al. Irradiation of pediatric high-grade spinal cord tumors. Int J Radiat Oncol Biol Phys. 2010;78:1451-1456.
27. Johung TB, Monje M. Diffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targets. Curr Neuropharmacol. 2017;15:88-97.
28. Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas—current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017;19:1025-1034.
29. Bużkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128:573-581.
30. Khalid S, Kelly R, Carlton A, et al. Adult intradural intramedullary astrocytomas: a multicenter analysis. J Spine Surg. 2019;5:19-30.
31. Beneš V, Barsa P, Beneš V, Suchomel P. Prognostic factors in intramedullary astrocytomas: a multicenter analysis from 2006 to 2012. J Neurooncol. 2019;144(3):569-580.
32. Houten JK, Cooper PR. Spinal cord astrocytomas: presentation, management and outcome. J Neurooncol. 2000;47:219-224.
33. McGirt MJ, Goldstein IM, Chaichana KL, Tobias ME, Kothbauer KF, Jallo GI. Extent of surgical resection of malignant astrocytomas of the spinal cord: outcome analysis of 35 patients. Neurosurgery. 2008;63(1):55-61; discussion 60–51.
34. Guss ZD, Moningi S, Jallo GI, Cohen KJ, Wharam MD, Terezakis SA. Management of pediatric spinal cord astrocytomas: outcomes
35. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. *Front Oncol*. 2012;2:205.

36. Silveira AB, Kasper LH, Fan Y, et al. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. *Acta Neuropathol*. 2019;137:637-655.

37. Pan C, Diplas BH, Chen X, et al. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. *Acta Neuropathol*. 2018;137:297-306.

38. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. *Nat Genet*. 2012;44:251-253.

39. Yang P, Wang Y, Peng X, et al. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. *J Neurooncol*. 2013;113:259-266.

How to cite this article: Zhang Y-W, Chai R-C, Cao R, et al. Clinicopathological characteristics and survival of spinal cord astrocytomas. *Cancer Med*. 2020;9:6996–7006. https://doi.org/10.1002/cam4.3364